The emerging field of oncolytic virus-based cancer immunotherapy is a research paper published in Trends in cancer (2022). On theSindex it has a DataRank of 0.856. It has been cited 300 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.856
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Institutes of Health
Grant: AI129582
National Institutes of Health
Grant: CA163205
National Institutes of Health
Grant: CA210087
National Institutes of Health
Grant: CA223400
National Institutes of Health
Grant: CA247550
National Institutes of Health
Grant: CA264512
National Institutes of Health
Grant: CA265095
National Institutes of Health
Grant: CA266457
National Institutes of Health
Grant: NS106170
Leukemia and Lymphoma Society
Grant: 1364-19
NCI NIH HHS
Grant: R35 CA210087
NCI NIH HHS
Grant: R01 CA247550
NCI NIH HHS
Grant: R01 CA265095
NCI NIH HHS
Grant: R01 CA266457
NCI NIH HHS
Grant: R21 CA223400
NCI NIH HHS
Grant: P01 CA163205
NIAID NIH HHS
Grant: R01 AI129582
NINDS NIH HHS
Grant: R01 NS106170
NCI NIH HHS
Grant: U19 CA264512
NCI NIH HHS
Grant: P01 CA236749
MeSH Terms
Keywords
Additional file 1 of An oncolytic HSV-1 vector induces a therapeutic adaptive immune response against glioblastoma
Additional file 1 of An oncolytic HSV-1 vector induces a therapeutic adaptive immune response against glioblastoma